Copy to clipboard 
Globus reported 3Q25 orthopedic sales of $769 million, up 22.9% compared to the third quarter of 2024. Its base business, excluding Nevro, grew 7% in the quarter. For the first nine months of the year, the company generated $2.1 billion, up 13.5% over the prior period (3% on an organic basis).
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
Additionally, Globus’ launch of the ANTHEM plating line in trauma during the third quarter brought the company up to critical mass for its portfolio, which now covers about 80% of competitive lines. This allows Globus to bid on primary or preferred vendor contracts in its target accounts.
However, the company’s enabling technology sales remain challenged. While its deal pipeline remains robust, Globus said deals are slower to close because of more competitive systems in the market and hospital economics. The company, which traditionally sold most of its robots outright, has introduced more capital efficient ways for hospitals to place its technology.
“There’s more competition that’s hit the market,” said Globus Medical CEO Keith Pfeil. “One of the things that we see is that hospitals are requiring surgeons to go through the review of all the offerings that are out there. That has kind of elongated some of the deals. As I think about what I’ve seen from hospitals, what I’ve seen publicly disclosed and just what I’ve heard anecdotally, hospitals are spending money on things like growing out ASCs or building new facilities that might not always be focused on surgical robotics.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $583.1 | $533.3 | $49.8 | 9.3% |
| Trauma | $18.6 | $15.9 | $2.7 | 17.2% |
| Orthobiologics | $40.0 | $38.2 | $1.8 | 4.8% |
| Enabling Technology | $28.0 | $38.3 | ($10.3) | (26.8%) |
| Other | $99.3 | |||
| Total | $769.0 | $625.7 | $143.3 | 22.9% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $1,640.7 | $1,572.3 | $68.3 | 4.3% |
| Trauma | $78.6 | $68.6 | $10.0 | 14.6% |
| Orthobiologics | $114.0 | $114.1 | ($0.1) | (0.1%) |
| Enabling Technology | $85.4 | $107.1 | ($21.7) | (20.2%) |
| Other | $193.9 | |||
| Total | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $617.6 | $495.8 | $121.8 | 24.6% |
| OUS | $151.4 | $129.9 | $21.5 | 16.5% |
| Total | $769.0 | $625.7 | $143.3 | 22.9% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,702.3 | $1,478.2 | $224.1 | 15.2% |
| OUS | $410.2 | $383.9 | $26.4 | 6.9% |
| Total | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $769.0 | |
| Cost of Sales | $252.5 | 32.8% |
| R & D | $38.1 | 4.9% |
| Selling and Admin | $313.6 | 40.8% |
| Other | $45.9 | 6% |
| Net Earnings | $119.0 | 15.5% |
Globus reported 3Q25 orthopedic sales of $769 million, up 22.9% compared to the third quarter of 2024. Its base business, excluding Nevro, grew 7% in the quarter. For the first nine months of the year, the company generated $2.1 billion, up 13.5% over the prior period (3% on an organic basis).
The company has put together 32 weeks of...
Globus reported 3Q25 orthopedic sales of $769 million, up 22.9% compared to the third quarter of 2024. Its base business, excluding Nevro, grew 7% in the quarter. For the first nine months of the year, the company generated $2.1 billion, up 13.5% over the prior period (3% on an organic basis).
The company has put together 32 weeks of consecutive sales growth for U.S. spine sales, with balanced contributions coming from all tracked product categories. U.S. spine sales grew 9.6% in the third quarter, with momentum carrying into the fourth quarter.
Additionally, Globus’ launch of the ANTHEM plating line in trauma during the third quarter brought the company up to critical mass for its portfolio, which now covers about 80% of competitive lines. This allows Globus to bid on primary or preferred vendor contracts in its target accounts.
However, the company’s enabling technology sales remain challenged. While its deal pipeline remains robust, Globus said deals are slower to close because of more competitive systems in the market and hospital economics. The company, which traditionally sold most of its robots outright, has introduced more capital efficient ways for hospitals to place its technology.
“There’s more competition that’s hit the market,” said Globus Medical CEO Keith Pfeil. “One of the things that we see is that hospitals are requiring surgeons to go through the review of all the offerings that are out there. That has kind of elongated some of the deals. As I think about what I’ve seen from hospitals, what I’ve seen publicly disclosed and just what I’ve heard anecdotally, hospitals are spending money on things like growing out ASCs or building new facilities that might not always be focused on surgical robotics.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $583.1 | $533.3 | $49.8 | 9.3% |
| Trauma | $18.6 | $15.9 | $2.7 | 17.2% |
| Orthobiologics | $40.0 | $38.2 | $1.8 | 4.8% |
| Enabling Technology | $28.0 | $38.3 | ($10.3) | (26.8%) |
| Other | $99.3 | |||
| Total | $769.0 | $625.7 | $143.3 | 22.9% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $1,640.7 | $1,572.3 | $68.3 | 4.3% |
| Trauma | $78.6 | $68.6 | $10.0 | 14.6% |
| Orthobiologics | $114.0 | $114.1 | ($0.1) | (0.1%) |
| Enabling Technology | $85.4 | $107.1 | ($21.7) | (20.2%) |
| Other | $193.9 | |||
| Total | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $617.6 | $495.8 | $121.8 | 24.6% |
| OUS | $151.4 | $129.9 | $21.5 | 16.5% |
| Total | $769.0 | $625.7 | $143.3 | 22.9% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,702.3 | $1,478.2 | $224.1 | 15.2% |
| OUS | $410.2 | $383.9 | $26.4 | 6.9% |
| Total | $2,112.5 | $1,862.1 | $250.4 | 13.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $769.0 | |
| Cost of Sales | $252.5 | 32.8% |
| R & D | $38.1 | 4.9% |
| Selling and Admin | $313.6 | 40.8% |
| Other | $45.9 | 6% |
| Net Earnings | $119.0 | 15.5% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
